Latest & greatest articles for budesonide

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on budesonide or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on budesonide and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for budesonide

101. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group. (PubMed)

A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group. Crohn's disease is often treated with glucocorticoids or mesalamine. We compared the efficacy and safety of controlled-ileal-release budesonide capsules and slow-release mesalamine tablets in patients with active Crohn's disease affecting the ileum, the ascending colon, or both.In a double-blind, multicenter trial, we enrolled 182 patients with scores of 200 to 400 (...) on the Crohn's Disease Activity Index (with higher scores indicating greater disease activity) and randomly assigned 93 to receive 9 mg of budesonide once daily and 89 to receive 2 g of mesalamine twice daily for 16 weeks. The primary efficacy variable was clinical remission, defined as a score of 150 or less on the Crohn's Disease Activity Index.In the analysis of all patients who received at least one dose of study drug, the rates of remission after 8 weeks of treatment were 69 percent in the budesonide

1998 NEJM

102. Cost effectiveness of fluticasone and budesonide in patients with moderate asthma

Cost effectiveness of fluticasone and budesonide in patients with moderate asthma Cost effectiveness of fluticasone and budesonide in patients with moderate asthma Cost effectiveness of fluticasone and budesonide in patients with moderate asthma Steinmetz K O, Volmer T, Trautmann M, Kielhorn A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions (...) followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Inhaled fluticasone (metered dose inhaler) was compared to inhaled budesonide (Turbuhaler(R) in corticosteroid-naive patients with moderate asthma. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The authors did not define the study population. The study sample comprised patients enrolled in a multi-centre trial, who were aged between

1998 NHS Economic Evaluation Database.

103. Cost-effectiveness of budesonide controlled ileal release (CIR) capsules as maintenance therapy versus no maintenance therapy for ileocaecal Crohn's disease in Sweden

Cost-effectiveness of budesonide controlled ileal release (CIR) capsules as maintenance therapy versus no maintenance therapy for ileocaecal Crohn's disease in Sweden Cost-effectiveness of budesonide controlled ileal release (CIR) capsules as maintenance therapy versus no maintenance therapy for ileocaecal Crohn's disease in Sweden Cost-effectiveness of budesonide controlled ileal release (CIR) capsules as maintenance therapy versus no maintenance therapy for ileocaecal Crohn's disease (...) in Sweden Noble I, Brown R, Danielsson A, Ericsson K, Floren C H, Hertzman P, Lofberg R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Using budesonide controlled ileal release (CIR) capsules 6mg per day as maintenance therapy

1998 NHS Economic Evaluation Database.

104. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. (PubMed)

Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. The role of long-acting, inhaled beta2-agonists in treating asthma is uncertain. In a double-blind study, we evaluated the effects of adding inhaled formoterol to both lower and higher doses of the inhaled glucocorticoid budesonide.After a four-week run-in period of treatment with budesonide (800 microg twice daily), 852 patients being (...) treated with glucocorticoids were randomly assigned to one of four treatments given twice daily by means of a dry-powder inhaler (Turbuhaler): 100 microg of budesonide plus placebo, 100 microg of budesonide plus 12 microg of formoterol, 400 microg of budesonide plus placebo, or 400 microg of budesonide plus 12 microg of formoterol. Terbutaline was permitted as needed. Treatment continued for one year; we compared the frequency of exacerbations of asthma, symptoms, and lung function in the four groups

1997 NEJM

105. A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. (PubMed)

A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. Inhaled glucosteroids and oral theophylline are widely used to treat asthma. We compared the benefits of adding theophylline to inhaled glucosteroid with those of doubling the dose of inhaled glucosteroid in patients with persistent symptoms despite the use of inhaled glucosteroid.In a double-blind, placebo-controlled trial, we randomly assigned 62 patients to receive either 400 (...) microg of inhaled budesonide (low-dose budesonide) with 250 or 375 mg of theophylline (depending on body weight) or 800 microg of inhaled budesonide (high-dose budesonide). All doses were given twice daily for three months. Lung function was measured serially, and patients kept records of peak expiratory flow, symptoms, and albuterol use. The effects of treatment on endogenous cortisol levels were also assessed.Both treatments resulted in improvements in lung function that were sustained throughout

1997 NEJM

106. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. (PubMed)

Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. In a previous study, we found that two years of treatment with an inhaled corticosteroid, budesonide, was more effective than treatment with an inhaled beta 2-agonist, terbutaline, in patients with newly diagnosed, generally mild asthma. We continued this study for a third year to investigate whether the steroid dose could be reduced or discontinued and what effect crossover of patients from beta 2-agonist (...) therapy to corticosteroid therapy would have.A total of 37 patients treated for two years with inhaled budesonide at a dose of 1200 micrograms per day were randomly assigned to treatment with 400 micrograms of budesonide per day (19 patients) or placebo (18 patients) in a double-blind manner. Another 37 patients, who had received terbutaline during the first two years, were crossed over in an open-label manner to treatment with 1200 micrograms of budesonide per day during the third year.Treatment

1994 NEJM

107. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. (PubMed)

Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. Corticosteroids are the most efficacious drugs for inducing remission in active Crohn's disease, but their benefits are frequently offset by serious side effects. Budesonide is a corticosteroid with high topical antiinflammatory activity but low systemic activity because of extensive hepatic metabolism. We investigated the efficacy and safety of an oral controlled-ileal-release preparation of budesonide (...) in patients with active Crohn's disease involving the ileum or ileum and proximal colon.In a double-blind, multicenter trial, 258 patients were randomly assigned to receive placebo or one of three doses of budesonide--3, 9, or 15 mg daily. The primary outcome measure was clinical remission, as defined by a score of 150 or less on the Crohn's disease activity index.After eight weeks of treatment, remission occurred in 51 percent of the patients in the group receiving 9 mg of budesonide (95 percent

1994 NEJM

108. A comparison of budesonide with prednisolone for active Crohn's disease. (PubMed)

A comparison of budesonide with prednisolone for active Crohn's disease. Patients with active Crohn's disease are often treated with corticosteroids, but the treatment has many side effects. Budesonide is a potent, well-absorbed corticosteroid, but because of a high rate of first-pass metabolism in the liver, its systemic bioavailability is low.We conducted a randomized, double-blind, 10-week trial comparing the efficacy and safety of an oral controlled-release form of budesonide (...) with the efficacy and safety of prednisolone in 176 patients with active ileal or ileocecal Crohn's disease (88 patients in each treatment group). The dose of budesonide was 9 mg per day for eight weeks and then 6 mg per day for two weeks. The dose of prednisolone was 40 mg per day for two weeks, after which it was gradually reduced to 5 mg per day during the last week.At 10 weeks, 53 percent of the patients treated with budesonide were in remission (defined as a score < or = 150 on the Crohn's disease activity

Full Text available with Trip Pro

1994 NEJM

109. Nebulized budesonide for children with mild-to-moderate croup. (PubMed)

Nebulized budesonide for children with mild-to-moderate croup. Although recent evidence has strongly supported the use of glucocorticoid therapy in children hospitalized with croup, the benefit of this therapy in children with less severe croup has not been documented. This randomized, double-blind trial compared a nebulized glucocorticoid, budesonide, with placebo in outpatients with mild-to-moderate croup.Children three months to five years of age were eligible for the study if their croup (...) scores fell in the mild-to-moderate range (scores of 2 to 7 out of a possible 17). The patients were randomly assigned to receive either 2 mg (4 ml) of nebulized budesonide (27 children) or 4 ml of nebulized normal saline (27 children); they were then assessed hourly for up to four hours by investigators who were unaware of the assigned treatments.The median croup score at entry into the study was 4 in both groups. At the final study assessment, the median score was significantly lower

1994 NEJM

110. Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. (PubMed)

Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. The presence of airway inflammation even in mild asthma points to the potential value of antiinflammatory therapy. We compared the effect of an inhaled corticosteroid, budesonide, with that of an inhaled beta 2-agonist, terbutaline, in the long-term treatment of newly detected asthma.We studied 103 patients (29 male and 74 female patients 15 to 64 years old) in whom asthma had (...) appeared within the previous year. The patients were randomly assigned in blinded fashion to two treatment groups: one to receive 600 micrograms of inhaled budesonide twice a day, and the other to receive 375 micrograms of inhaled terbutaline twice a day. The study period was two years.After six weeks of treatment, the patients treated with budesonide tolerated inhaled histamine better than the patients treated with terbutaline (a difference of one doubling dose step, P less than 0.001

1991 NEJM

111. Growth of asthmatic children during treatment with budesonide: a double blind trial. (PubMed)

Growth of asthmatic children during treatment with budesonide: a double blind trial. To determine whether the inhaled glucocorticosteroid budesonide has any adverse effect on short term linear growth in children with mild asthma.Outpatient clinic in secondary referral centre.15 children aged 6-13 years with normal statural growth velocity during the previous year, no signs of puberty, and no use of systemic or topical steroids in the two months before the study. DESIGN OF INTERVENTIONS: Double (...) blind, randomised crossover trial with two active periods in which budesonide was given in divided daily doses of 200 micrograms and 800 micrograms. During run in and two washout periods placebo was given. After the second washout period the children received open treatment with 400 micrograms budesonide daily. All periods were of 18 days' duration.Growth of the lower leg as measured twice a week by knemometry.Mean growth velocity of the lower leg was 0.63 mm/week during run in and during washout

Full Text available with Trip Pro

1991 BMJ

112. Inhaled budesonide for treatment of recurrent wheezing in early childhood. (PubMed)

Inhaled budesonide for treatment of recurrent wheezing in early childhood. 77 children, aged 11 to 36 months (mean 24) with moderately severe recurrent wheezing, were treated with budesonide pressurised aerosol 400 micrograms twice daily or placebo for 12 weeks in a double-blind, parallel-group trial. Aerosols were inhaled from a spacer with a facemask. Budesonide significantly improved symptom scores of wheezing, sleep disturbance, and patient happiness. The frequency of severe exacerbations

1990 Lancet

113. Controlled trial of budesonide given by the nebuhaler in preschool children with asthma. (PubMed)

Controlled trial of budesonide given by the nebuhaler in preschool children with asthma. To determine whether the inhaled corticosteroid budesonide, given by a Nebuhaler spacing device, was effective in prophylaxis of asthma in preschool children.Double blind, placebo controlled, random order crossover trial with two week practice run in period.Outpatient clinic referrals in secondary referral centre.39 children aged 2-6 years selected for the following: able to use Nebuhaler; parents able (...) to complete record card; poorly controlled asthma (defined); not already on systemic or inhaled steroids. Eleven withdrew for various reasons not connected with intolerance to budesonide. Age, sex, other atopies, and symptoms during run in period were similar in the 28 children who completed the trial and in the 11 who withdrew.Budesonide 200 micrograms or placebo (both one puff) given twice daily during 6-week treatment or control periods, using Nebuhaler after prior training. Three week "washout

Full Text available with Trip Pro

1988 BMJ